LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Core Insights - LIXTE Biotechnology Holdings, Inc. is focused on advancing its lead compound LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), while pursuing strategic acquisitions in oncology [1][2][4] Group 1: Clinical Execution - The company is committed to the continued advancement of LB-100 across prioritized tumor settings, supported by growing clinical and preclinical evidence [8] - Ongoing proof-of-concept clinical trials for LB-100 are in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [5] Group 2: Strategic Expansion - LIXTE is entering Q4 2025 with clear operational goals and a disciplined approach to strategic expansion, focusing on high-need cancer indications [2][3] - The company is in advanced negotiations for potential acquisitions of complementary oncology assets to enhance its pipeline and accelerate development [2][8] Group 3: Operational Readiness - The company is undertaking initiatives in quality, chemistry, manufacturing, and regulatory alignment to support efficient study conduct and potential integration of acquired programs [8]